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Opinion statement
An important issue in relation to the utility and reliability of biomarkers for asthma monitoring
is how asthma is defined and characterized. What kind of asthma, or at what stage of the
disease is a particular biomarker supposed to add information? Often, the purpose, or useful-
ness of a biomarker is not made clear. Diagnosis, severity evaluation, and monitoring are all
different clinical uses for a biomarker, and confusion may arise when a biomarker is suitable for
one of these but not another. When the utility of available biomarkers are discussed, these
different roles need to be clarified. Our opinion is that there are four aspects of relevance to
asthma, for which biomarkers are required: to diagnose allergies, to evaluate inflammation in
the airways, to evaluate hyper-responsiveness, and for certain measures of lung function, such
as lung clearance index. These types of biomarkers are needed for the phenotyping and
monitoring of asthma. Another important role for biomarkers is, as mentioned above, to
monitor asthma in order to follow treatment effects on inflammation and hyper-
responsiveness as objective adjuncts to the patients’ own symptom reports and lung function.
This review will mainly focus on biomarkers that reflect airway inflammation. In spite of the
numerous studies that have been conducted, we still have to remember that the value of
biomarkers available for routine use, such as eosinophil counts in blood and sputum and
exhaled nitric oxide, have to be interpreted in relation to reported symptoms and lung function.
Measures of bronchial hyper-responsiveness, performed either by direct (methacholine chal-
lenge) or indirect (exercise or mannitol challenge) methods, could be considered biomarkers
but will not be included in this review. On the other hand, diagnosing allergy is not usually
useful for monitoring asthma although it is of fundamental importance for the interpretation of
most biomarkers that are suitable for monitoring. We have therefore included the different
approaches for diagnosing and evaluating allergic sensitization in this review.
Introduction
Asthma is the single most prevalent handicap among
children [1], with a prevalence of up to 15 % reported
in certain European countries according to the Inter-
national Study of Asthma and Allergies in Childhood
(ISAAC) [2]. However, this is not one disease with a
common underlying mechanism. It is now well
known that asthma is a heterogenous disorder with
many clinical phenotypes, and the symptoms of air-
way obstruction and bronchial hyper-responsiveness
may be driven by several different biological path-
ways [3•]. The most recently updated GINA guide-
lines address these issues by stressing the importance
of standardized diagnosis and assessment when con-
sidering appropriate treatment strategies [4••]. While
the majority of children with asthma have mild or
moderate disease and can be adequately controlled
by avoiding relevant trigger factors and taking appro-
priate medications, there is still a group of children
with severe asthma in whom symptom control re-
mains poor. A lot of research has been performed in
recent years aimed at revealing new biomarkers spe-
cific for certain phenotypes, in order to improve the
diagnosis and treatment of different asthma subtypes,
especially those which are more severe and therapy
resistant. New and expensive treatment possibilities
require a more individual biomarker approach to
target the patients that will benefit the most.
This review will describe biomarkers currently in
use for the phenotyping and monitoring of asthma in
children but also discuss potential new biomarkers
along with their advantages and disadvantages, with a
focus on suitability and ease of use in pediatric care.
Exhaled breath
As a matrix, exhaled air is the most non-invasive kind available, and a range of
different methodologies, new andmore established, make use of this matrix for
the assessment of airway inflammation.
Exhaled nitric oxide
The most studied is the measurement of exhaled NO (FeNO), which can be
analyzed in a quick and easy way, mostly in school-age children although
techniques are available to enable measurement even in the very young [5].
FeNO has been shown to correlate with bronchial hyper-responsiveness, blood
eosinophils, serum eosinophil cationic protein (ECP), and atopic status/
immunoglobulin E (IgE) levels in children [6]. As its levels tend to be reduced by
corticosteroid treatment [7], high NO levels may identify children with atopic
asthma that are likely to respond to corticosteroid treatment [8]. Furthermore,
low exhaledNO in childrenwith asthmamay reflect a sub-type of asthma that is
less likely to respond to steroid treatment. The exact cutoff values have been
described in ATS guidelines published in 2011 [9•].
Nevertheless, despite this vast body of promising findings and even clinical
guidelines, the clinical circumstances in which FeNO is able to give the most
beneficial results is currently debated, and the link between FeNO and disease
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severity may be complex [9•]. Petsky and colleagues concluded that measuring
FeNO did not improve asthma outcomes in a meta-analysis of three studies
examining the benefit of FeNO in guiding the treatment of asthmatic children
[10]. The same conclusion is expressed in a recently published review [11••]
although the trends toward FeNO measurements contributing to reduced ex-
acerbations and increased medication use are pointed out. Different future uses
of FeNO measurements may include analyses of FeNO fluctuation in combi-
nation with methods that quantify cross-correlations with symptoms for indi-
cating exacerbation risk, as opposed to the use of isolated FeNOmeasurements
[12]. FeNO measurements in combination with another biomarker may also
provide additional clinical information as compared to FeNOalone. Konradsen
et al. recently demonstrated that FeNO in combination with blood eosinophil
numbers, one local and one systemic marker of Th2-mediated inflammation,
were able to identify children with a high asthma morbidity to a greater extent
than either marker alone [13]. In another Swedish study of children and young
adults, the combination of increased FeNO levels and blood eosinophil counts
related to a higher prevalence of severe BHR and uncontrolled asthma [14]. A
further interesting example is a study in which regular use of the Asthma
Control Test (ACT) to guide therapy was compared to standard visits with or
without measurement of FeNO. The results show that both approaches have
their advantages and limitations [15•].
Volatile organic compounds
A more novel approach is that of the analysis of volatile organic compounds
(VOC) in exhaled air, or the eNose. This is an Bomics^ approach in that it involves
the profiling of multiple metabolic compounds originating from the lungs and
upper airways. The technique used to measure these compounds is usually gas
chromatography coupledwithmass spectrometry (GC-MS), and thismethod has
been found to differentiate between adults with asthma, COPD, and healthy
controls [16, 17]. In children with asthma, VOC analysis enabled prediction of
subsequent exacerbations [18] and interestingly, young pre-school children with
rhinovirus-induced wheeze were found to have altered exhaled biomarkers both
during symptoms and after resolution, possibly reflecting the altered molecular
profile which underlies an increased risk of developing asthma [19]. Breath
analysis by eNose has even been found to predict response to steroids in patients
with asthma more accurately than sputum eosinophils or FeNO [20]. Taken
together, these findings suggest that the eNose may be a promising, non-invasive
tool worth considering for the future diagnosis and monitoring of children with
asthma in highly specialized centers.
Exhaled breath condensate
Another matrix related to exhaled air is that of exhaled breath condensate
(EBC), which is composed of the droplets collected when exhaled breath is
cooled. This matrix may be of use for certain future biomarker analyses, such as
measures of oxidative stress. Elevated levels of hydrogen peroxide [21], nitrates
and nitrites [22], and 8-isoprostane [23] have all been reported in the EBC of
patients with asthma compared to healthy controls. However, there are many
methodological concerns surrounding the use of EBC. For example, while
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differences in leukotrienes have been reported in the EBC from asthmatic
children compared to healthy controls [24], it has also been shown that any LTs
present in EBC are entirely due to salivary contamination [25]. Therefore, the
use of EBC for biomarker analysis requires further methodological validation.
Blood
Obtaining blood samples may be associated with some discomfort in children,
but this technique is still considered to be minimally invasive. The blood
volumes necessary for cell counting andmost biomarker measurements are low
and considered to be of low risk for children [26].
Blood cell counts
Performing differential blood cells counts may provide information regarding
asthma phenotypes in adults with asthma [27]. In adults, high blood eosino-
phil numbers show associations with higher total IgE, lower FEV1, more exac-
erbations, and corticosteroid sensitivity [27, 28]. High blood neutrophil num-
bers on the other hand tend to correlate with current smoking and non-atopic
asthma [27].
Increased blood eosinophils are often observed in pediatric asthma and
do show a relationship with disease severity [29]. Another potential for the
utility of eosinophil counts in blood is as a marker of response to cortico-
steroids in pre-school children [30]. However, it has also been shown that
blood eosinophil levels do not correlate well with airway eosinophils in
children with severe asthma [31•], so use as a single surrogate marker for
tissue eosinophila is not recommended. As mentioned above, a combina-
tion of eosinophil count and FeNO could reflect both local and peripheral
signs of airway inflammation [13, 32]. This combination needs to be
evaluated in larger prospective trials for monitoring asthma.
Blood eosinophil counts have also been mentioned in relation to re-
sponse to omalizumab treatment. Busse and coworkers reported high eo-
sinophil counts to be a potential biomarker capable of reflecting successful
omalizumab treatment effects [33]. Further, a combination of three
markers, namely, blood eosinophils, FeNO, and periostin, were shown to
identify a group of children and adults that had the lowest exacerbation
frequency during 48 weeks of omalizumab therapy [34].
Less is known concerning the relevance of blood neutrophil numbers in
children, but certain studies do report increased blood neutrophils in chil-
dren with more severe asthma or in the very young with wheeze [35, 36].
Immunoglobulin
It is of little doubt that measurement of serum IgE levels can provide important
information for the clinical diagnosis of atopic asthma. Measuring allergen-
specific IgE levels sheds light on sensitizing allergens, thus enabling the avoid-
ance of trigger factors, and total IgE levels can indicate a general predisposition
toward atopic asthma [36]. To highlight the importance of IgE as a biomarker, a
specialist NIH task force states that a semi-quantitative screen of specific IgE
against common aeroallergens (Phadiatop), in combination with the fx5 panel
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of food allergens in children younger than 15 years, should be considered core
biomarker measurements to be performed in prospective clinical trials and
observational studies [26]. Interestingly, more sputum eosinophils have been
reported in children with food allergies and asthma, compared to children
without food allergies suggesting that there may be a link between food allergy
and certain asthma subtypes that requires further investigation [37]. A mea-
surement of total IgE is required before omalizumab treatment can be started
but has no role in evaluating the effect of therapy. The basophil allergen
threshold sensitivity may be a possible tool in evaluating response to anti-IgE
therapy [38].
Certain limitations regarding the methods of total and specific IgE mea-
surements mentioned are that they only provide information about the possi-
ble source of the sensitizing allergen, but no information regarding sensitiza-
tion toward specific allergenic components and thereby knowledge of potential
cross-reactivities. Secondly, allergen-specific IgE antibody counts do not always
reflect the response of the relevant effector cells and the clinical symptoms that
follow upon exposure to allergen. Allergen provocation tests are therefore
required, but they cannot always be performed in children with severe asthma
due to the risk involved. We therefore describe two approaches whichmay help
to overcome these limitations.
IgE against allergen components
Cross-sensitization may be explained by the fact that similar epitopes arise in
allergens from different sources [39]. Whereas some allergens may be exclusive
to a particular source, othersmay arise fromdifferent sources, yet share the same
structure and function. New techniques that may help us to identify these
allergens involve component specific methodologies, which can determine
both the sources of the sensitizing allergens and the origin of the cross-reactive
allergens [40]. In addition, it may be possible to predict whether the ensuing
reaction experienced by a patient will bemild or severe, based on the allergen to
which they are sensitized. Severely asthmatic children with peanut allergy who
are allergic to peanut and sensitized to Ara h 1, Ara h 2, and Ara h 3 allergens are
at risk of more life-threatening reactions upon exposure to peanut, compared
with children sensitized to Ara h 8 [41], a homolog of the main Birch pollen
allergen, Bet v 1.
In children with severe asthma, it may be of added benefit to perform such
an analysis as Nordlund et al. discovered increased sensitization toward the
animal-derived components lipocalin, secretoglobin, and kallikrein in children
with problematic, severe asthma as compared to children with more well-
controlled asthma [42]. The utility of component resolved analysis in relation
to animal dander allergy and asthma is discussed in a review [43•].
Basophil allergen threshold sensitivity (CD-sens)
A relatively new development that may enable improved assessment of the
degree of response to a given allergen is that of the basophil allergen threshold
sensitivity test (or CD-sens). CD-sens is alternative to clinical allergen provo-
cation tests performed in vitro which has been shown to correlate with the
results of in vivo allergen challenges [44]. This method involves the detection of
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CD63 on basophils following an in vitro allergen titration, and it can reveal the
sensitivity of basophils to a specific allergen. Children with mild and severe
asthma who were allergic to cats showed differences in CD-sens despite similar
levels of circulating cat-specific IgE [45]. As mentioned above, CD-sens is also a
possible biomarker of response to treatment with omalizumab [38].
Periostin
As its name suggests, periostin was first discovered to be secreted by cells of the
periosteum, and it was found to be involved in bone growth and repair [46]. In
addition, this matricellular protein is now known to be secreted bymany other,
predominantly structural cell types throughout the body such as epithelial cells
and fibroblasts, and its role seems to be a general involvement in fibrosis and
maintenance of the extracellular matrix [47]. Periostin is thought to be involved
in type 2-mediated airway inflammation due to its over-expression in epithelial
cells from adult asthmatic patients, specific up-regulation by classic type 2
cytokines IL-4 and IL-13, and its ability to determine the response of asthma
patients toward anti-IL-13 therapy [48–50].
Despite the interest in periostin as a potential biomarker of type 2 inflam-
mation in asthma, studies examining relationships between circulating
periostin levels and airway eosinophilia, as well as other type 2 biomarkers, are
relatively few,mostly limited to adults, and somehave shown conflicting results
[51, 52]. Nevertheless, the majority of published reports in adults do demon-
strate modest, yet significant relationships between circulating periostin with
other proposed markers of type 2 inflammation, including exhaled NO, spu-
tum, and blood eosinophils or total IgE [53–55].
However, despite the initial associations with eosinophilic asthma observed
in adults, periostin is unlikely to be a useful biomarker of type 2 inflammation
in children. Small increases in periostin levels have been reported in children
with asthma compared to healthy controls at certain, but not all, ages [56], and
moderate relationships with blood eosinophils and IgE have also been ob-
served [57]. However, baseline periostin levels are high in children, most likely
due to bone growth, which may mask changes due to local release within the
airways. This is a major confounding factor and most likely the reason for
inconsistent findings regarding periostin as a marker of type 2 asthma in
children. No correlations between serum periostin and FeNO, blood eosino-
phils, or IgE were found in school-age children with moderate or severe asthma
[13], or in children aged 6 to 11 with various manifestations of allergic disease,
including asthma [58].
YKL-40
One unmet need in biomarker research is the discovery of markers which may
reflect non-type 2 driven asthma. A mediator which has shown potential for this
purpose is YKL-40, a chitinase-like protein which is elevated in the serum of both
school-age children and adults with severe asthma. Increased circulating YKL-40
consistently associates with reduced lung function, strengthening a possible
relationship with disease severity [59–62]. The exact biological function of YKL-
40 remains unclear, but the fact that it associates with measures of airway
remodeling such as bronchial wall thickness and subepithelial fibrosis [59, 60]
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and increases the proliferation of bronchial smoothmuscle cells [63, 64] is in line
with an involvement in airway remodeling and fibrotic lung disease [65].
YKL-40 levels are higher in adults with COPD compared to asthma [62] and,
preliminarily, in children with BPD compared to asthma [66], suggesting that the
chitinases are not Th2-specific markers of airway disease. Also, correlations often
exist between YKL-40 levels and neutrophilic, rather than eosinophilic inflam-
mation [60, 67]. However, further studies are required to establish whether YKL-
40 measurements are of clinical value and if YKL-40 has any potential in the
monitoring of persistent asthma.
Others
Novel blood biomarkers that may be associated with asthma in children
are continuously emerging, and it is beyond the scope of this review to
describe them all, but thymic stromal lymphopoetin (TSLP) is an
epithelial-derived Balarmin^ cytokine worth mentioning as a promising
example [68]. Little is known about its circulating levels in pediatric
cohorts, although an increase in children with asthma compared to con-
trols, as well as an association with asthma control, has been reported
[69]. Measuring circulating 25-OH Vitamin D levels in the clinic may also
be of interest as several pediatric studies now describe an association
between Vitamin D deficiency and increased risk of asthma, as well as
asthma severity [70–72]. The field of biomarker discovery is exploding
with novel biomarkers due to the increasing application of Bomics^ tech-
nologies. For example, Hamsten and colleagues recently drew attention to
the differential expression of chemokine ligand 5 (CCL5), hematopoietic
prostaglandin D synthase (HPGDS), and neuropeptide S receptor 1
(NPSR1) in the plasma of children with asthma using an antibody-based
proteomic array [73]. Further validation will reveal whether these new
Bhits^ are of clinical value.
Lower airway samples
Sputum
Induced sputum is a relatively safe, semi-invasive method which can be gener-
ally be performed well by school-age children assisted by specially trained staff
[74]. Different cellular compositions have been described in children (eosino-
philic, neutophilic, mixed granulocytic, and paucigranulocytic), which may
relate to different asthma phenotypes [75]. It has been shown that sputum
eosinophil numbers are higher in atopic as compared to non-atopic childhood
asthma [76]. As well as cellular profile, it is also possible to measure soluble
inflammatory mediators in sputum supernatants. Cytokine profiles in sputum
supernatant from children with asthma have both been described as altered
[76], and unaltered as compared to healthy controls [77]. Interestingly, recent
findings from our own group suggest that sputum IL-26 may be a novel
biomarker of pediatric asthma without signs of Th2-mediated or eosinophilic
inflammation [78]. This is of particular interest as the biological mechanisms
underlying non-Th2-driven asthma remain elusive. However, it must be noted
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that there is no evidence to suggest that the analysis of induced sputum samples
is clinically useful for the monitoring of asthma in children. Sputum cell
profiles have been shown to be unstable over time [75] and have failed to
successfully guide anti-inflammatory treatment [79].
Bronchoscopic procedures
Obtaining bronchial brushings, biopsies, and lavage fluid from children is
possible, but these are invasive procedures that can only be performed in
specialized centers and tend only to be performed to evaluate airway inflam-
mation in children with very severe therapy-resistant asthma [80]. Although not
routinely performed in children, valuable research findings have been obtained
in recent years from the transcriptome analyses performed using bronchial
brushings (epithelial cells) collected from adults. Woodruff and colleagues
established a BTh2-high^ signature by grouping subjects based on elevated
expression of three bronchial epithelial genes: CLCA1, periostin, and serpinB2.
Patients in this Th2-high group had more airway eosinophils and bronchial
hyper-responsiveness and were responsive to inhaled corticosteroids therapy as
opposed to those in the BTh2-low group^ [49].
Urine
Collecting urine is an extremely non-invasive process which would make it an
ideal matrix for the measurement of biomarkers and monitoring of childhood
asthma. However, there are currently no urinary biomarkers that are routinely
examined in a clinical setting to assess airway inflammation in children with
asthma. Nevertheless, promising findings from research studies suggest that
there may be a place for routine urine sampling in children with asthma,
particularly for the measurement of eicosanoids and their metabolites.
Eicosanoids
The involvement of leukotrienes, prostaglandins, and other arachidonic acid-
derived lipid mediators in asthma and airway inflammation has long been
known. The cysteinyl leukotrienes (Cys-LTs) are among the most potent
bronchoconstrictive agents known and also have chemotactic, mucous secretory,
and pro-fibrotic effects in the airways [81]. Different prostaglandins (PGs) acting
at their respective receptors are also clearly involved in both pro- (e.g., PGD2)
and anti-inflammatory (e.g., PGE2) processes in airway disease [82]. Despite
their well-known biological activity, these mediators have sometimes proven
difficult to measure due to their rapid metabolism and clearance from the
circulation which has hampered their use as biomarkers [83, 84]. However, as an
alternative to blood, the analysis of lipid mediator metabolites (rather than
primary compounds) excreted into the urine has emerged as a non-invasive
biomarker. Reproducible liquid chromatography coupled to mass spectrometry
(LC-MS)-based platforms have recently been developed specifically for this
purpose [85]. Two urinary eicosanoid metabolites which are considered to be of
particular interest in asthma are 11β-PGF2α and LTE4 by virtue of their abilities
to reflect mast cell and eosinophil activation, respectively.
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Urinary LTE4 has been found to increase during asthma exacerbations,
caused by both inhaled aspirin and allergen challenges [86–88]. Furthermore,
drugs that block Cys-LT synthesis significantly decrease urinary LTE4 levels [89],
whereas corticosteroids do not affect urinary LTE4 [86]. Primary PGD2 is not
detectable in urine, and its earliest appearing metabolite is 11β-PGF2α [90].
Several lines of evidence suggest that 11β-PGF2α levels in the urine reflect mast
cell activation in the lung. Its levels are increased by inhaled allergen challenge
and inhaled mannitol challenge, as well as during aspirin- and exercise-induced
bronchoconstriction in susceptible individuals [91]. Again, mast cell PGD2
release is not significantly affected by corticosteroid treatment [92], although the
mast cell-stabilizing drug sodium cromoglycate may prevent its release [93].
Preliminary findings from our group suggest that children with asthma who
had high levels of urinary LTE4 or 11β-PGF2α (above the 75th percentile), as
compared to those with low levels (below the 25th percentile), had a lower
FEV1, increased bronchial responsiveness, increased IgE, and increased blood
eosinophils, factors which may well reflect a more type 2-driven airway inflam-
mation [94]. The future of urinary lipid metabolites as phenotype-specific
biomarkers in asthma is likely to develop further as the platforms used evolve to
incorporate increased numbers of metabolites, thus enabling a more complete
overview of arachidonic acid metabolism [85].
Eosinophil-derived neurotoxin
Another class of mediators that may be measured in the urine, and which
have received renewed interest in recent years, are eosinophil-derived
proteins such as eosinophil protein X (EPX, also currently known as EDN,
eosinophil-derived neurotoxin). These are eosinophil granule-derived
proteins, the advantage of which being that they may reflect eosinophil
activation, rather than eosinophil numbers, which may be of more rele-
vance to active inflammatory disease processes. Over the years, research
studies have shown conflicting findings, but a recent meta-analysis taking
into account 27 childhood studies conducted over a 20-year period con-
cluded that over 70 % of these did show an association between EPX and
childhood asthma, thus implicating a clinical role for EPX measurements
[95]. Future studies will confirm whether this is the case and if EDN in
urine could be used for monitoring of asthma in children.
Conclusions
Despite the continuing emergence of promising new biomarkers for the phe-
notyping andmonitoring of asthma in children, we still must acknowledge that
our understanding of the molecular mechanisms underlying different asthma
phenotypes is limited. Of all the biomarkers discussed above, only one or two
are currently used in the clinic, and these mostly in specialist clinics. The most
studied biomarker is FeNO, yet in spite of this, it is still considered equivocal
although there is evidence that high levels can predict risk of exacerbation.
Generally, biomarkers or physiologicalmeasures that precisely and conclusively
define sub-phenotypes of asthma are lacking. Before many of the potential
biomarkers described in this review can enter clinical practice, a great deal more
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validation is required in studies of well-characterized asthmatic children [96•].
Normal ranges need to be established, and stability over time must be exam-
ined in longitudinal studies. We need to know more about the effects of
medications on biomarker measurements, especially for biomarkers which are
proposed to guide different treatments [97••]. Knowledge of confounding
factors is vital as highlighted above by the effect of age, and thereby growth, on
periostin levels. Finally, and most importantly, any new biomarkers need to be
easily sampled and easy to interpret at the point of care in order to provide
better treatment for those children who need it the most. A combination of
non-invasive biomarkers and the use of electronic devices to enable patients to
report symptoms and lung function will hopefully initiate a more personalized
approach to health care and improve adherence to therapy.
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